ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.18 Million GBP | -34.26% |
| 2022 | 11.62 Million GBP | -7.46% |
| 2021 | 12.56 Million GBP | -38.92% |
| 2020 | 20.57 Million GBP | 7.54% |
| 2019 | 19.13 Million GBP | -6.31% |
| 2018 | 20.41 Million GBP | 2.44% |
| 2017 | 19.93 Million GBP | 44.94% |
| 2016 | 13.75 Million GBP | 31.94% |
| 2015 | 10.42 Million GBP | 30.45% |
| 2014 | 7.99 Million GBP | 12.47% |
| 2013 | 7.1 Million GBP | 2.61% |
| 2012 | 6.92 Million GBP | 3.42% |
| 2011 | 6.69 Million GBP | 69.15% |
| 2010 | 3.95 Million GBP | -17.54% |
| 2009 | 4.8 Million GBP | -30.59% |
| 2008 | 6.91 Million GBP | 15.0% |
| 2007 | 6.01 Million GBP | 1.16% |
| 2006 | 5.94 Million GBP | 78.12% |
| 2005 | 3.33 Million GBP | 0.97% |
| 2004 | 3.3 Million GBP | -31.73% |
| 2003 | 4.84 Million GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 645.5 Thousand GBP | -76.93% |
| 2024 Q2 | 640 Thousand GBP | -0.85% |
| 2023 FY | 7.64 Million GBP | -34.26% |
| 2023 Q4 | 2.79 Million GBP | 258.72% |
| 2023 Q2 | 4.58 Million GBP | 606.25% |
| 2023 Q1 | 648.5 Thousand GBP | -87.89% |
| 2023 Q3 | 779.99 Thousand GBP | -82.97% |
| 2022 Q4 | 5.35 Million GBP | 522.31% |
| 2022 Q3 | 860.5 Thousand GBP | -85.54% |
| 2022 FY | 11.62 Million GBP | -7.46% |
| 2022 Q1 | 838 Thousand GBP | -83.92% |
| 2022 Q2 | 5.95 Million GBP | 610.26% |
| 2021 Q1 | 1.03 Million GBP | -87.95% |
| 2021 FY | 12.56 Million GBP | -38.92% |
| 2021 Q4 | 5.21 Million GBP | 399.57% |
| 2021 Q3 | 1.04 Million GBP | -86.37% |
| 2021 Q2 | 7.65 Million GBP | 641.5% |
| 2020 Q2 | 11.59 Million GBP | 978.2% |
| 2020 Q4 | 8.56 Million GBP | 861.39% |
| 2020 Q1 | 1.07 Million GBP | 0.89% |
| 2020 FY | 20.57 Million GBP | 7.54% |
| 2020 Q3 | 890.99 Thousand GBP | -92.32% |
| 2019 Q3 | 1.06 Million GBP | 16.57% |
| 2019 Q1 | 914.49 Thousand GBP | -37.81% |
| 2019 FY | 19.13 Million GBP | -6.31% |
| 2019 Q4 | 1.06 Million GBP | 0.0% |
| 2019 Q2 | 914.49 Thousand GBP | 0.0% |
| 2018 Q3 | 1.47 Million GBP | 13.73% |
| 2018 Q2 | 1.29 Million GBP | 0.0% |
| 2018 Q1 | 1.29 Million GBP | -25.69% |
| 2018 FY | 20.41 Million GBP | 2.44% |
| 2018 Q4 | 1.47 Million GBP | 0.0% |
| 2017 Q2 | 523.99 Thousand GBP | 0.0% |
| 2017 FY | 19.93 Million GBP | 44.94% |
| 2017 Q1 | 523.99 Thousand GBP | -41.62% |
| 2017 Q3 | 1.73 Million GBP | 232.06% |
| 2017 Q4 | 1.73 Million GBP | 0.0% |
| 2016 Q1 | 843.49 Thousand GBP | -33.19% |
| 2016 FY | 13.75 Million GBP | 31.94% |
| 2016 Q4 | 897.5 Thousand GBP | 0.0% |
| 2016 Q3 | 897.5 Thousand GBP | 6.4% |
| 2016 Q2 | 843.49 Thousand GBP | 0.0% |
| 2015 Q1 | 584 Thousand GBP | -41.34% |
| 2015 Q4 | 1.26 Million GBP | 0.0% |
| 2015 Q3 | 1.26 Million GBP | 116.18% |
| 2015 Q2 | 584 Thousand GBP | 0.0% |
| 2015 FY | 10.42 Million GBP | 30.45% |
| 2014 Q1 | 372.5 Thousand GBP | -27.53% |
| 2014 FY | 7.99 Million GBP | 12.47% |
| 2014 Q4 | 995.5 Thousand GBP | 0.0% |
| 2014 Q3 | 995.5 Thousand GBP | 167.25% |
| 2014 Q2 | 372.5 Thousand GBP | 0.0% |
| 2013 Q4 | 513.99 Thousand GBP | 0.0% |
| 2013 Q3 | 513.99 Thousand GBP | 0.0% |
| 2013 FY | 7.1 Million GBP | 2.61% |
| 2012 FY | 6.92 Million GBP | 3.42% |
| 2011 FY | 6.69 Million GBP | 69.15% |
| 2010 FY | 3.95 Million GBP | -17.54% |
| 2009 FY | 4.8 Million GBP | -30.59% |
| 2008 FY | 6.91 Million GBP | 15.0% |
| 2007 FY | 6.01 Million GBP | 1.16% |
| 2006 FY | 5.94 Million GBP | 78.12% |
| 2005 FY | 3.33 Million GBP | 0.97% |
| 2004 FY | 3.3 Million GBP | -31.73% |
| 2003 FY | 4.84 Million GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agentix Corp. | 1.37 Million USD | -131.965% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 36.891% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 12.839% |
| Biomind Labs Inc. | 994.18 Thousand USD | -220.062% |
| ContraFect Corporation | 56.88 Million USD | 94.407% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -137.189% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -21.103% |
| CSL Limited | 3.44 Billion USD | 99.908% |
| CytoDyn Inc. | 18.05 Million USD | 82.379% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 89.233% |
| GB Sciences, Inc. | 1.42 Million USD | -124.004% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -70.674% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 6.549% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -716.806% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1345.851% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.46% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -665.863% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -111.865% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -244.555% |
| Skye Bioscience, Inc. | 13.54 Million USD | 76.512% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 91.459% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.284% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -55.318% |
| Zenith Capital Corp. | 8.94 Million USD | 64.419% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.333% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -9.113% |
| Mesoblast Limited | 5.9 Million USD | 46.086% |
| Marizyme, Inc. | 19.23 Million USD | 83.461% |
| Genus plc | 147.7 Million USD | 97.846% |
| Pharming Group N.V. | 225.49 Million USD | 98.589% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 61.842% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -115.181% |
| IMV Inc. | 37.7 Million USD | 91.562% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -14.036% |
| MultiCell Technologies, Inc. | 567.42 USD | -560683.899% |
| ONE Bio Corp. | 6.44 Million USD | 50.62% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.298% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 87.125% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -80.829% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 52.635% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 12828.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 80.125% |
| Alpha Cognition Inc. | 9.7 Million USD | 67.215% |
| Enzolytics Inc. | 2.17 Million USD | -45.996% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.793% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -204.789% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -32.311% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.614% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 35.298% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1115.775% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -29.596% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1755.296% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -65.651% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 63.755% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 27.824% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | 15.066% |
| Helix BioMedix, Inc. | 1.97 Million USD | -61.356% |
| EV Biologics, Inc. | 531.96 Thousand USD | -498.163% |
| Q BioMed Inc. | 3.43 Million USD | 7.409% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 70.719% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.797% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 86.15% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -73.397% |
| HST Global, Inc. | 140.9 Thousand USD | -2158.227% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -138.275% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -182.867% |
| Halberd Corporation | 74.84 Thousand USD | -4151.623% |
| Resverlogix Corp. | 12.71 Million USD | 74.969% |
| Cell Source, Inc. | 4.32 Million USD | 26.434% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -101.475% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 56.472% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -18165.312% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -28.995% |
| Kadimastem Ltd | 2.41 Million USD | -32.027% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 24.925% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1653.313% |
| LadRx Corporation | 3.81 Million USD | 16.522% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -244.555% |
| Affymax, Inc. | 39.38 Million USD | 91.921% |
| Itoco Inc. | 919.14 Thousand USD | -246.192% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -184.361% |
| Mobile Lads Corp. | 554.54 Thousand USD | -473.803% |
| International Stem Cell Corporation | 5.27 Million USD | 39.632% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | 16.705% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -12542.536% |
| Qrons Inc. | 643.67 Thousand USD | -394.347% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -124.117% |
| SYBLEU INC | 160.87 Thousand USD | -1877.921% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -42.698% |
| Rebus Holdings, Inc. | 664 Thousand USD | -379.217% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -75.189% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5944.603% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -15541.744% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.226% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -96.663% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -332.434% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -2.282% |
| Neutra Corp. | 243.82 Thousand USD | -1205.056% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 81.772% |
| PureTech Health plc | 144.59 Million USD | 97.799% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 84.47% |
| IXICO plc | 4.7 Million USD | 32.399% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 63.829% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.298% |
| CSL Limited | 3.89 Billion USD | 99.918% |
| Cellectis S.A. | 97.32 Million USD | 96.73% |